Selected Publications
Slater RL, Lai Y, Zhong Y, Li H, Meng Y, Homet Moreno B, Godwin JL, Frenkl T, Sonpavde GP, Mamtani R.: The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. J Med Econ : 2020.
Bange EM, Doucette A, Gabriel PE, Porterfield F, Harrigan JJ, Wang R, Wojcieszynski AP, Boursi B, Mooney BI, Reiss KA, Mamtani R.: Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JCO Oncol Pract : 2020.
Takvorian SU, Oganisian A, Mamtani R, Mitra N, Shulman LN, Bekelman JE, Werner RM.: Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status, Cancer Stage, and Timely Treatment Among Patients With Breast, Colon, and Lung Cancer JAMA Netw Open : 2020.
Parikh RB, Feld EK, Galsky MD, Adamson BJ, Cohen AB, Baxi SS, Boursi SB, Christodouleas JP, Vaughn DJ, Meropol NJ, Mamtani R.: First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. Future Oncol : 2020.
Parikh RB, Feld EK, Galsky MD, Adamson BJ, Cohen AB, Baxi SS, Boursi SB, Christodouleas JP, Vaughn DJ, Meropol NJ, Mamtani R.: First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis Future Oncol. : 2019.
Vajravelu RK, Copelovitch L, Osterman MT, Scott FI, Mamtani R, Lewis JD, Denburg MR.: Risk for Chronic Kidney Disease in Patients with Inflammatory Bowel Diseases Increases with Age but is not Associated with 5-aminosalicylate Use Clin Gastroenterol Hepatol pii: S1542-3565 (19): 31245-5,2019.
Corbett CJ, Xia L, Mamtani R, Malkowicz SB, Guzzo TJ.: Survival Benefit Persists With Delayed Initiation of Adjuvant Chemotherapy Following Radical Cystectomy for Locally Advanced Bladder Cancer. Urology 132 : 143-149,2019.
Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R.: Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer Eur Urol. 76 (4): 524-532,2019.
Margalit O, Mamtani R, Lawrence YR, Yang YX, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.: Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy. Clin Colorectal Cancer 18 (3): 226-230,2019.
Parikh R, Adamson B, Galsky M, Khozin S, Baxi S, Cohen A, Mamtani R.: Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer JAMA 322 (12): 1209-1211,2019.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia,
PA
19147
Phone: 215-662-7606
Patient appointments: 800-789-7366